BG105162A - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
BG105162A
BG105162A BG105162A BG10516201A BG105162A BG 105162 A BG105162 A BG 105162A BG 105162 A BG105162 A BG 105162A BG 10516201 A BG10516201 A BG 10516201A BG 105162 A BG105162 A BG 105162A
Authority
BG
Bulgaria
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
BG105162A
Other languages
Bulgarian (bg)
English (en)
Inventor
Thomas BOCAN
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of BG105162A publication Critical patent/BG105162A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
BG105162A 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions BG105162A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
BG105162A true BG105162A (en) 2001-12-29

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105162A BG105162A (en) 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (xx)
JP (1) JP2002521328A (xx)
KR (1) KR20010083134A (xx)
CN (1) CN1310629A (xx)
AP (1) AP2001002035A0 (xx)
AU (1) AU4701799A (xx)
BG (1) BG105162A (xx)
BR (1) BR9912296A (xx)
CA (1) CA2335062A1 (xx)
CZ (1) CZ2001126A3 (xx)
EA (1) EA200100153A1 (xx)
EE (1) EE200100046A (xx)
HR (1) HRP20010055A2 (xx)
HU (1) HUP0102880A3 (xx)
ID (1) ID30030A (xx)
IL (1) IL140982A0 (xx)
IS (1) IS5809A (xx)
NO (1) NO20010291L (xx)
OA (1) OA11584A (xx)
PL (1) PL346011A1 (xx)
SK (1) SK502001A3 (xx)
TR (1) TR200100205T2 (xx)
WO (1) WO2000004892A2 (xx)
YU (1) YU3501A (xx)
ZA (1) ZA200100294B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
WO2002020009A1 (fr) * 2000-09-01 2002-03-14 Sankyo Company, Limited Compositions medicales
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
AU2003229883B2 (en) * 2002-04-03 2009-06-11 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
KR101011373B1 (ko) * 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 항균작용을 갖는 ｎ-히드록시아미드 유도체
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
EP3244883A1 (en) * 2015-01-15 2017-11-22 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US6117909A (en) * 1995-08-04 2000-09-12 Warner-Lambert Company Methods of using sulfamic acid derivatives for lowering serum or plasma level of Lp(a)
PT901466E (pt) * 1996-05-17 2002-04-29 Warner Lambert Co Bifenilsulfonamidas como inibidores de metaloproteinases da matriz
EP0931045A1 (en) * 1996-09-04 1999-07-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
KR20010083134A (ko) 2001-08-31
PL346011A1 (en) 2002-01-14
NO20010291D0 (no) 2001-01-18
CN1310629A (zh) 2001-08-29
IL140982A0 (en) 2002-02-10
HRP20010055A2 (en) 2002-04-30
TR200100205T2 (tr) 2001-05-21
WO2000004892A3 (en) 2000-05-18
AU4701799A (en) 2000-02-14
CA2335062A1 (en) 2000-02-03
WO2000004892A2 (en) 2000-02-03
JP2002521328A (ja) 2002-07-16
CZ2001126A3 (cs) 2002-01-16
ZA200100294B (en) 2002-01-10
OA11584A (en) 2004-07-20
YU3501A (sh) 2005-06-10
EE200100046A (et) 2002-06-17
SK502001A3 (en) 2002-06-04
EP1098662A2 (en) 2001-05-16
BR9912296A (pt) 2001-04-17
EA200100153A1 (ru) 2001-08-27
HUP0102880A2 (en) 2002-06-29
HUP0102880A3 (en) 2002-11-28
NO20010291L (no) 2001-01-18
ID30030A (id) 2001-11-01
IS5809A (is) 2001-01-12
AP2001002035A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
BG105162A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
EP1100392A4 (en) METHODS AND DEVICES FOR REDUCING THE MINERAL CONTENT OF VASCULAR CALCIFIED LESIONS
EP1319404A3 (de) Mittel zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
ZA200104118B (en) Substituted benzimidazoles and their use as PARP inhibitors.
CY1109636T1 (el) Συνθεση στοματικης δοσης παρατεταμενης απελευθερωσης
IL128080A0 (en) Thiol sulfonamide metalloprotease inhibitors
IL141957A0 (en) 5ht1 receptor agonists and metoclopramide for the treatment of migraine
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
GB9804886D0 (en) Therapeutic combination
EP0964686A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING THE DEVELOPMENT OF ATHEROSCLERIC LESIONS
HUP0103424A3 (en) Use of eletriptan for the prevention of migraine recurrence
FR2744621B1 (fr) Determination des tunnels femoral et tibial pour la reconstruction isometrique du ligament croise anterieur
AU2002230390A1 (en) Ixodes scapularis tissue factor pathway inhibitor
IT1302813B1 (it) Dispositivo per la riduzione diretta di ossidi di ferroe relativo procedimento
AU4144099A (en) Use of an agent for the prevention of gum disease
GB9824875D0 (en) Use of an agent for the prevention of gum disease
YU23901A (sh) Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera
MXPA02011810A (es) Utilizacion del riluzol o sus sales para la prevencion y el tratamiento de la adrenoleucodistrofia.
EP1115687A4 (en) 5,6-DIHYDRONAPHTHALENYL DERIVATIVES WITH RETINOID-LIKE ACTIVITY
HUP9903964A3 (en) Methods and compositions for preventing or retarding the development of atherosclerotic lesions
TW374520U (en) Increasing and deducting structure for the metal guide foot of the computer line terminals
IT1321047B1 (it) Procedimento e dispositivo per il rilevamento dell'avvenutadisattvazione di un dispositivo di frenatura, particolarmente per un
KR960014949U (ko) 브레이크 라이닝의 마모감지장치